Advertisement
Canada markets close in 6 hours 20 minutes

  • S&P/TSX

    21,658.66
    -215.06 (-0.98%)
     

  • S&P 500

    4,998.79
    -72.84 (-1.44%)
     

  • DOW

    37,898.38
    -562.54 (-1.46%)
     

  • CAD/USD

    0.7286
    -0.0012 (-0.16%)
     

  • CRUDE OIL

    83.06
    +0.25 (+0.30%)
     

  • Bitcoin CAD

    86,760.80
    -4,016.23 (-4.42%)
     

  • CMC Crypto 200

    1,343.44
    -39.13 (-2.83%)
     

  • GOLD FUTURES

    2,329.10
    -9.30 (-0.40%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.7290
    +0.0770 (+1.66%)
     

  • NASDAQ

    15,383.78
    -328.97 (-2.09%)
     

  • VOLATILITY

    17.01
    +1.04 (+6.51%)
     

  • FTSE

    8,048.46
    +8.08 (+0.10%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6815
    -0.0004 (-0.06%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

Stocks in play: Revive Therapeutics Ltd.

Baystreet.ca
·1 min read

Announced it has signed a supply agreement with Havn Life Sciences Inc. (CSE:HAVN ) (FRA:5NP) to source naturally-derived psychedelic compounds, such as psilocybin, for use in future investigational new drug enabling studies and clinical trials under the Food and Drug Administration guidelines. "We are excited about our strategic partnership with Havn Life as one of our suppliers of psychoactive compounds that we intend to develop and commercialize using our established tannin-chitosan based proprietary oral-thin film delivery system, for the pharmaceutical and wellness markets,” said Michael Frank, Revive’s Chief Executive Officer. Revive Therapeutics Ltd. shares C.RVV are trading down 1.96 percent at $0.25.

Read: Microgrids Are the Next Big Growth Opportunity in the Energy Markets